SP2509 是有效，选择性的 LSD1 拮抗剂，IC₅₀ 值为 13 nM。

SP2509 is a potent and selective antagonist of lysine specific demethylase 1 (LSD1) with an IC 50 of 13 nM.

Solid

IC50: 13 nM (LSD1)

SP2509 (250, 500, 1000 nM) inhibits LSD1 activity, depletes colony growth and induces apoptosis and cell death of cultured human acute myeloid leukemia cells, and increases H3K4Me3 on the promoters of p57 Kip, KLF4, and p21 and induces mRNA expression of p57Kip, KLF4 and p21 in AML cells. SP2509 (250, 1000 nM) induces features of morphologic differentiation of cultured and primary AML cells. Besides, SP2509 in combination with PS exerts synergistic lethal activity against cultured and primary AML cells. SP2509 does not destabilize the CoREST-LSD1 interaction, and has no major destabilizing effect on the CRC. SP2509 (1 or 10 μM) induces cell death, but there are no morphological changes at a low concertation of 0.1 μM. SP2509 likewise interferes with the viability of medulloblastoma cells. has not independently confirmed

Treatment with SP2509 (25 mg/kg) and/or PS (5 mg/kg) significantly enhances PS-mediated loss of viability of CD34 primary AML cells and improves the survival of mice bearing AML xenografts and primagrafts. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

4°C, protect from light In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

[1]. Fiskus W, et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 2014 Nov;28(11):2155-64.
[2]. Inui K, et al. Stepwise assembly of functional C-terminal REST/NRSF transcriptional repressor complexes as a drug target. Protein Sci. 2017 Feb 20

In Vitro: DMSO : ≥ 33 mg/mL (75.36 mM)配制储备液